Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.91 USD
Change Today -0.39 / -3.17%
Volume 293.2K
RMTI On Other Exchanges
RMTI is not on other exchanges.
As of 2:33 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

rockwell medical inc (RMTI) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/17/15 - $18.90
52 Week Low
12/10/14 - $8.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ROCKWELL MEDICAL INC (RMTI)

Related News

No related news articles were found.

rockwell medical inc (RMTI) Related Businessweek News

No Related Businessweek News Found

rockwell medical inc (RMTI) Details

Rockwell Medical, Inc. operates as an integrated biopharmaceutical company in the United States and internationally. It offers products and services for the treatment of end-stage renal disease, chronic kidney disease, iron deficiency, secondary hyperparathyroidism, and hemodialysis. The company’s products are used to cleanse patients' blood and replace nutrients lost during the kidney dialysis process. Its lead drug include Triferic, an iron compound that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron loss that occurs during their dialysis treatment. The company also provides Calcitriol, a generic active vitamin D indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, it manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric-acid concentrate, Dri-Sate dry acid concentrate, Renal Pure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company sells its products directly to hemodialysis providers, as well as through independent sales agents and distributors. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.

283 Employees
Last Reported Date: 03/3/15
Founded in 1995

rockwell medical inc (RMTI) Top Compensated Officers

Founder, Chairman of The Board, Chief Executi...
Total Annual Compensation: $1.3M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $501.9K
Chief Medical Officer
Total Annual Compensation: $541.0K
Chief Scientific Officer and Member of Scient...
Total Annual Compensation: $586.1K
Compensation as of Fiscal Year 2014.

rockwell medical inc (RMTI) Key Developments

Rockwell Medical, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Rockwell Medical, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported sales of $12,955,576 against $13,033,361 a year ago. Operating loss was $2,654,898 against $2,382,008 a year ago. Loss before income taxes was $2,536,747 against $3,170,378 a year ago. Net loss was $2,536,747 or $0.05 per diluted share against $3,170,378 or $0.08 per diluted share a year ago. For the six months, the company reported sales of $26,839,537 against $25,997,013 a year ago. Operating loss was $6,467,907 against $9,407,446 a year ago. Loss before income taxes was $6,235,941 against $10,975,904 a year ago. Net loss was $6,235,941 or $0.12 per diluted share against $10,975,904 or $0.28 per diluted share a year ago. Cash used in operating activities was $9,702,831 against $13,611,724 a year ago. Purchase of equipment was $208,613 against $428,831 a year ago.

Rockwell Medical, Inc., Q2 2015 Earnings Call, Aug 04, 2015

Rockwell Medical, Inc., Q2 2015 Earnings Call, Aug 04, 2015

Rockwell Medical Announces Triferic(TM) Phase 3 Cruise Studies Published in Nephrology Dialysis Transplantation

Rockwell Medical, Inc. announced the publication of Triferic Phase 3 CRUISE studies (CRUISE 1 and 2) in Nephrology Dialysis Transplantation (NDT). Triferic is the only FDA approved iron product indicated for delivery via dialysate to replace iron and maintain hemoglobin in hemodialysis patients in the United States. The CRUISE studies were randomized, single blind, placebo controlled, efficacy and safety studies in chronic hemodialysis patients. Triferic was added to the bicarbonate hemodialysis concentrate while placebo patients received standard hemodialysate without Triferic. A total of 599 patients participated in both studies with 290 randomized to receive Triferic and 295 to placebo. Patients completed the Phase 3 study when they met pre-specified anemia centered criteria or lasted 48 weeks without achieving the criteria. After completing randomized treatment, patients entered open-label treatment. The primary objective of the CRUISE studies was to determine whether regular administration of Triferic via dialysate could maintain hemoglobin concentrations by optimizing iron delivery and maintaining iron balance. The primary endpoint was the mean change in hemoglobin from baseline to the end-of-treatment (EoT) defined as the average of all hemoglobin values obtained during the last one-sixth (1/6th) of the time spent in the randomized stage of treatment (Stage 2). Both studies successfully met the primary endpoint with a treatment difference of 0.4 g/dL in hemoglobin concentration in favor of Triferic (P=0.011 for individual studies, 95% confidence interval 0.1 to 0.6 g/dL). During the randomized treatment phase, hemoglobin concentrations remained stable in the Triferic treated group while declined in the placebo group. The safety profile of Triferic was similar to placebo treated patients, with both groups experiencing similar proportions of adverse events. The most frequent adverse event was procedural hypotension which was present in 21.6% of Triferic patients and 19.2% of placebo treated patients. No serious adverse events or deaths were attributed to Triferic. The CRUISE article, Ferric pyrophosphate citrate (Triferic) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RMTI:US $11.91 USD -0.39

RMTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.34 USD -0.68
Fresenius Medical Care AG & Co KGaA €68.01 EUR -0.202
View Industry Companies

Industry Analysis


Industry Average

Valuation RMTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.2x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCKWELL MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at